New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 13, 2014
07:37 EDTENTAEnanta Pharmaceuticals reports Q1 EPS (30c), consensus (15c)
Reports Q1 revenue $893K, consensus $1.41M. The company said, "The changes in revenue for the three-month periods are primarily related to the timing and amount of milestone and other payments from collaborations, which have varied significantly from period to period and are expected to continue to do so."
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
17:33 EDTENTAS&P announces changes to S&P 400, 500, and 600 indices
Subscribe for More Information
17:19 EDTENTAEnanta to replace PAREXEL in S&P 600 as of 7/28 close
14:56 EDTENTAEnanta announces FDA approval of AbbVie's Technivie
Enanta Pharmaceuticals (ENTA) announced that the FDA approved AbbVie’s (ABBV) Technivie -- ombitasvir, paritaprevir and ritonavir -- tablets in combination with ribavirin for the treatment of non-cirrhotic adults with genotype 4 chronic hepatitis C virus, or HCV, infection. Technivie is the first and only all-oral, interferon-free, direct-acting antiviral treatment approved in the U.S. for adult patients with GT4 chronic HCV infection. Paritaprevir is Enanta’s lead protease inhibitor identified within the ongoing Enanta-AbbVie collaboration and is one of the two direct-acting antivirals (2-DAA) in AbbVie’s Technivie.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use